Piper Sandler Initiates Coverage On Tyra Biosciences with Overweight Rating, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Tyra Biosciences (NASDAQ:TYRA) with an Overweight rating and a price target of $33.
August 15, 2024 | 9:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Tyra Biosciences with an Overweight rating and a price target of $33.
The initiation of coverage with an Overweight rating and a price target of $33 by Piper Sandler is likely to positively impact Tyra Biosciences' stock price in the short term. Such analyst ratings often lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100